Abstract
Recent studies suggest that class III antiarrhythmic agents may have enhanced efficacy in the treatment of ventricular tachycardia. This study describes the first clinical assessment of the new class III agent ibutilide to suppress inducible monomorphic ventricular tachycardia (VT) in human beings. Fifty-five patients with coronary artery disease and inducible sustained monomorphic VT at baseline received either low (0.005 mg/kg + 0.001 mg/kg, load and maintenance infusion, respectively), middle (0.01 mg/kg + 0.002 mg/kg), or high dose (0.02 mg/kg + 0.004 mg/kg) infusions of ibutilide followed by repeat programmed ventricular stimulation. The mean age of the study group was 65.5 +/- 9.5 years and mean left ventricular ejection fraction was 36% +/- 11%. Of 48 evaluable patients, 21 (44%) were rendered noninducible after ibutilide, with no difference in efficacy among the three dosing groups (p = 0.83). Ventricular effective refractory periods, QTc interval, and ventricular monophasic action potential duration were prolonged over baseline at all tested cycle lengths. The QTc and action potential prolongation were dose related. Serious drug-related adverse reactions included sustained polymorphic VT in two patients (3.6%), spontan...Continue Reading
References
Nov 1, 1992·Pacing and Clinical Electrophysiology : PACE·J D FisherJ Roth
Nov 3, 1992·European Journal of Pharmacology·M G CiminiJ K Gibson
Apr 1, 1992·American Heart Journal·P T SagerW P Batsford
May 1, 1990·Pacing and Clinical Electrophysiology : PACE·W SchoelsW Kuebler
Jan 1, 1992·Journal of the American College of Cardiology·D J Callans, F E Marchlinski
Jan 2, 1990·The American Journal of Cardiology·K Nademanee, B N Singh
Jan 2, 1990·The American Journal of Cardiology·L F SoykaR B Spangenberg
Aug 1, 1987·Circulation·J J MahmarianC M Pratt
Apr 1, 1984·Journal of Clinical Pharmacology·E M Vaughan Williams
Dec 1, 1995·Circulation·P R KoweyM M Scheinman
Feb 1, 1995·Journal of Cardiovascular Pharmacology·J J LynchC M Woods
Mar 15, 1995·Circulation·T YangD M Roden
Aug 12, 1993·The New England Journal of Medicine·J W Mason
Jul 1, 1996·Journal of the American College of Cardiology·K A EllenbogenJ T Vanderlugt
Oct 1, 1996·Circulation·B S StamblerJ T VanderLugt
Citations
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·A J Camm, Y G Yap
Feb 7, 2001·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·K A Marill, T Runge
May 24, 2000·Progress in Pediatric Cardiology·A Dubin
Oct 30, 2015·Expert Opinion on Pharmacotherapy·J William SchleiferWin-Kuang Shen
Jun 24, 2004·Expert Opinion on Investigational Drugs·Anirban Choudhury, Gregory Y H Lip
Jun 2, 2005·Expert Opinion on Investigational Drugs·Sheila A Doggrell, Jules C Hancox
Dec 16, 2000·Journal of Cardiovascular Pharmacology·H R LuF De Clerck
Dec 24, 2018·Journal of Cardiovascular Electrophysiology·Mauricio Sendra-Ferrer, Mario D Gonzalez
Apr 17, 2020·Cardiovascular Drugs and Therapy·Ning ZhangLiqun Wu